All News

20 November 2024

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without InhibitorsAntibodies

20 November 2024

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian CancerDNA RNA and Cells

20 November 2024

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B VirusAntibodies

20 November 2024

Lilly’s muvalaplin lowered lipoprotein(a) levels in adults with high risk forSmall Molecules

20 November 2024

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergenceProteins and Peptides

20 November 2024

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline resultsProteins and Peptides

20 November 2024

Telix to Add FAP-Targeting Candidates to Theranostic PipelineMore News

20 November 2024

Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical StudySmall Molecules

20 November 2024

Virion Therapeutics Reports First-Ever Clinical Responses with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at AASLD’s The Liver Meeting®DNA RNA and Cells

20 November 2024

ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 – The Liver Meeting®Proteins and Peptides

20 November 2024

Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis BDNA RNA and Cells

20 November 2024

UCB receives U.S. FDA approval for BIMZELX® (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativaAntibodies

19 November 2024

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityAntibodies

19 November 2024

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell CarcinomaDNA RNA and Cells

19 November 2024

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 ProgramsAntibodies

19 November 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramAntibodies

19 November 2024

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant AscitesAntibodies

19 November 2024

Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in ChicagoDNA RNA and Cells

19 November 2024

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary EndpointsAntibodies

19 November 2024

AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Virus Repression with Tune-401 Epigenetic SilencerDNA RNA and Cells

19 November 2024

Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in AdultsAntibodies

19 November 2024

Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 VaccineVaccines

18 November 2024

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisDNA RNA and Cells

18 November 2024

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024Small Molecules

18 November 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR ConvergenceDNA RNA and Cells

18 November 2024

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceDNA RNA and Cells

18 November 2024

Lilly’s tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesityProteins and Peptides

18 November 2024

AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024DNA RNA and Cells

18 November 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific SessionsDNA RNA and Cells

18 November 2024

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

2023 Sales of Antibodies & Proteins

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPC3-Targeted Immunotherapy Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Her3-Targeted Immunotherapy Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review